Thoracic cancer

This early-stage trial is testing whether a new type of CAR-T cell therapy is safe for people with malignant pleural mesothelioma, a rare and aggressive cancer of the lung lining. The CAR-T cells are engineered to target a protein called mesothelin on cancer cells and include a b…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This early-phase trial is testing whether combining two drugs—erlotinib and irinotecan—can safely treat advanced solid tumors that have not responded to standard care. Erlotinib blocks signals that help cancer cells grow, while irinotecan is a chemotherapy drug that stops cancer …

This phase 2 trial is testing tarlatamab, an experimental drug given by IV, in 252 adults with small cell lung cancer that has worsened after platinum-based chemotherapy. The main goal is to see if the drug can shrink tumors (partial or complete response). Researchers will also m…

This study tests an experimental drug called CHO-H01, alone or with lenalidomide, in people with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The trial has two parts: first, finding a safe dose of CHO-H01 alone; second, testing the combination in l…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This phase III trial is testing whether the drug pyrotinib can further reduce the risk of breast cancer returning in women with HER2-positive early or locally advanced breast cancer who have already completed standard treatment with trastuzumab. Participants will be randomly assi…

This phase II trial tests a combination of immunotherapy (durvalumab), chemotherapy (carboplatin and paclitaxel), and targeted radiation to metastatic spots, followed by surgery or radiation to the main lung tumor. The goal is to see if this aggressive approach can keep the cance…

This study offers continued access to the cancer drug ruxolitinib (sometimes combined with other therapies) for people with pancreatic, colorectal, breast, or lung cancer who were already benefiting and stable in a prior Incyte-sponsored trial. Only 10 participants are enrolled, …

This trial tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer (NSCLC) that is PD-L1 negative. The goal is to see if the vaccine can train the immune system to destroy any remain…

This study tests whether adding the experimental drug capivasertib to standard hormone therapy and CDK4/6 inhibitors can delay cancer growth in people with advanced HR+/HER2- breast cancer that cannot be removed by surgery or has spread. About 895 adults whose cancer has not resp…

This phase 3 trial is testing a combination of two drugs—capivasertib (a pill that targets cancer cell growth) and fulvestrant (an injection that blocks estrogen)—in 258 Chinese patients with advanced HR+/HER2- breast cancer that has worsened after hormone therapy. The study focu…

This study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy (durvalumab) can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. The trial involves 60 adults with operable stage I…

This Phase 3 trial is testing whether a new drug called giredestrant, combined with palbociclib, works better than the standard letrozole plus palbociclib for people with a common type of advanced breast cancer (ER-positive, HER2-negative). About 992 participants will receive eit…

This study tests a daily pill called furmonertinib in about 100 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). Participants must have already tried chemotherapy. The goal is to see if the drug shrinks tumors and how sa…

This phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…

This Phase 3 trial compares a new drug called MK-2870 (sacituzumab tirumotecan) with standard chemotherapy (docetaxel or pemetrexed) in 556 adults with advanced non-squamous non-small cell lung cancer that has specific genetic changes (EGFR mutations or others) and has worsened a…

This phase 2 study compares two dosing schedules of the targeted drug adagrasib (Krazati) in 200 adults with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. Participants have already tried chemotherapy and immunotherapy. The goal is to see if a lower d…

This early-stage trial tests a personalized treatment for people with metastatic solid cancers that have KRAS mutations. Doctors take a patient's own white blood cells, genetically modify them to recognize and attack KRAS-mutated cancer cells, and return them to the patient along…

This study tests an experimental oral drug called JAB-21822 (glecirasib) in people with advanced solid tumors that have a specific mutation in the KRAS gene (G12C). The trial aims to find the best dose and check if the drug is safe and can shrink tumors. About 315 adults whose ca…

This early-stage trial is testing a new drug called GDC-9545 (giredestrant), alone or combined with other medications, in people with advanced ER-positive breast cancer that has spread. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 18…

This study tests whether a newer targeted drug, entrectinib, works better than the current standard drug, crizotinib, for people with advanced lung cancer that has a specific genetic change (ROS1). About 220 participants will take one of the two pills daily. The study focuses on …

This study tests a new drug called gotistobart (ONC-392) against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that worsened after prior immunotherapy. About 630 adults will receive either the new drug or chemotherapy every 3 weeks for up to…

This study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…

This phase II trial tested whether adding bevacizumab to osimertinib works better than osimertinib alone for patients with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the brain. Only 5 patients were enrolled. The goal was to see if t…

This pilot trial is testing whether a lower-toxicity chemotherapy combination can be a feasible option for adults aged 70 and older with HER2-negative breast cancer. The study aims to see how well older patients tolerate the treatment and whether they can complete the planned cou…

This early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…

This study tests a combination of two drugs—lorlatinib (a daily pill) and ramucirumab (an IV infusion every three weeks)—in people with advanced ALK-rearranged non-small cell lung cancer. The first part finds the safest dose, and the second part checks if that dose helps keep the…

This study tests a new drug called OP-1250 (palazestrant) against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can slow cancer growth better than standard care. The…

This trial is testing whether combining chemotherapy with two immunotherapy drugs, given before surgery, can completely eliminate triple-negative breast cancer in people with stage II-III disease. Participants will receive six cycles of the combination, and the main goal is to se…

This early-phase trial is testing two drugs, osimertinib and tegavivint, as a first treatment for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC that has spread). The goal is to find the best dose and see if the combination is safe and shrinks tumors. Abou…

This phase 2 trial tests whether adding petosemtamab to the standard immunotherapy pembrolizumab can shrink tumors in adults with metastatic non-small cell lung cancer. About 180 participants will receive the combination as their first treatment. The study focuses on how many pat…

This early-stage trial tests a personalized cell therapy called ADP-A2M4CD8 in people with certain cancers that have a specific marker (MAGE-A4). The therapy uses a patient's own immune cells, modified to better attack tumors, and is given alone or with standard immunotherapy dru…

This trial tests whether personalized nutrition counseling to increase fiber intake can help preserve the diversity of gut microbes in people undergoing treatment for early-stage triple-negative breast cancer. Participants are randomly assigned to receive either coaching from a r…

This early-stage trial tests a treatment called HER2-CAR T cells for people with HER2-positive cancers that have spread to the brain or its lining. The cells are given directly into the brain's fluid spaces to try to kill tumor cells. The main goals are to find the safest dose an…

This early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…

This study looks at the long-term safety of the drug enzalutamide in people with prostate cancer who have already been taking it in a previous study and are still benefiting. About 900 participants will continue their current treatment and be monitored for side effects. The goal …

This phase 2 trial is testing whether giving the targeted drug furmonertinib along with standard chemotherapy before surgery can shrink tumors in people with a specific type of lung cancer (EGFR-mutated, stage II to IIIB). Participants take furmonertinib daily for 9 weeks plus th…

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This phase 3 trial is testing whether the drug trastuzumab deruxtecan (T-DXd), alone or with other chemotherapy drugs, works better than standard treatment before surgery in people with high-risk HER2-positive early breast cancer. About 927 participants will receive one of three …

This phase 2 study tests two targeted drugs, encorafenib and binimetinib, in 119 people with advanced non-small cell lung cancer that has a specific BRAF V600E mutation. The goal is to see if the combination can shrink tumors and keep them from growing. Participants take the pill…

This study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…

This study tests whether a very low-carb (ketogenic) diet, a low-carb diet, or the diabetes drug canagliflozin can prevent high blood sugar and possibly make standard cancer therapy more effective. It involves 15 people with advanced, hormone-receptor-positive breast cancer that …

This phase III trial studies whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with stage 3 non-small cell lung cancer that cannot be surgically removed. About 660 participants will receive either chemoradiation plus durvaluma…

This study tests the drug trastuzumab deruxtecan in about 500 people with advanced HER2-positive breast cancer, some of whom also have brain metastases. The goal is to see how well the drug shrinks tumors and how long it keeps the cancer from growing. Participants receive the dru…

This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…

This early-stage trial tests a combination of two drugs—ceralasertib (a targeted therapy) and durvalumab (an immunotherapy)—in 14 Chinese patients with advanced solid tumours that have not responded to prior treatments. The main goal is to check safety and find the right dose. Re…

This study is testing whether giving radiation therapy tailored to each patient's risk level can reduce arm swelling (lymphedema) while still controlling cancer in women with early-stage breast cancer that has spread to a sentinel lymph node. Participants receive either whole bre…

This early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…

This Phase 3 trial tests whether an experimental drug called SIM0270 combined with everolimus works better than standard treatments for people with ER+/HER2- advanced or metastatic breast cancer that has worsened after CDK4/6 inhibitor therapy. About 460 participants will be rand…

This phase 2 study tests whether combining two targeted drugs, osimertinib and selumetinib, can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer who have not yet received EGFR inhibitors. The trial enrolls 25 participants and measures how well the tumo…

This early-phase trial is testing a combination of four drugs—ensartinib, two chemotherapy drugs, and a targeted antibody—in 12 people with advanced ALK-positive non-small cell lung cancer. The goal is to find the safest dose and see how well the combination controls the disease.…

This study offers ongoing treatment with the cancer drug durvalumab to people who have already completed a previous study and are still benefiting from the drug, as decided by their doctor. The main goal is to monitor safety and side effects. About 214 participants will be enroll…

This early-stage trial tests an experimental drug called SG2918 in 17 people with advanced cancers that no longer respond to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive the drug by IV every three w…

This study tests a new radiation technique called IMRT for people with malignant pleural mesothelioma, a rare lung cancer. The goal is to see if combining surgery, chemotherapy, and this targeted radiation is safe and reduces severe lung side effects. About 65 adults with early-s…

This study is for people with non-small cell lung cancer who have had chemotherapy and surgery. It tests whether adding a drug called AZD6738 to the immunotherapy drug durvalumab can help keep the cancer from coming back longer than durvalumab alone. About 630 adults with stage I…

This phase 2 trial is testing whether a chemotherapy combination without etoposide (carboplatin plus paclitaxel) plus the immunotherapy drug durvalumab works better than standard treatment for people with extensive-stage small cell lung cancer. About 67 participants will receive …

This phase 3 trial is comparing an experimental targeted drug called adagrasib (MRTX849) with the standard chemotherapy docetaxel in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and has already been treated. The study aims to see if adagr…

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…

This phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…

This study tests whether combining two drugs, atezolizumab and cobimetinib, can help people with advanced non-small cell lung cancer whose tumors stopped responding to standard immunotherapy. About 51 adults with metastatic or recurrent lung cancer will receive the combination. T…

This study tests three different immunotherapy drug combinations in people with advanced non-small cell lung cancer that has high PD-L1 levels and has not been treated before. The goal is to see if adding another immune-boosting drug to the standard anti-PD1 therapy can better co…

This study combines the CIMAvax EGF vaccine with immunotherapy drugs (nivolumab or pembrolizumab) to treat advanced non-small cell lung cancer and squamous head and neck cancer. The vaccine aims to slow tumor growth, while the immunotherapy helps the immune system attack cancer c…

This Phase 3 trial is testing a new daily pill called camizestrant against standard hormone therapies (like tamoxifen or aromatase inhibitors) in 5,500 people with ER+/HER2- early breast cancer who have a moderate-to-high risk of the cancer returning. Participants take the drug f…

This phase 2 trial tests whether adding an experimental immunotherapy (fianlimab) to standard immunotherapy (cemiplimab) and chemotherapy works better than the standard combo alone for people with early-stage lung cancer that can be removed by surgery. About 195 participants will…

This early-phase study tests whether a new treatment called KSQ-001EX is safe for people with advanced solid tumors like melanoma, lung cancer, or head and neck cancer. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are genetically modified …

This early-phase trial tests a drug called WSD0922-FU in 56 people with certain brain cancers (glioblastoma, anaplastic astrocytoma) or lung cancer that has spread to the brain or spinal cord. The drug blocks a protein called EGFR that helps cancers grow, and is designed to reach…

This trial tests whether starting to eat and move soon after lung cancer surgery (lobectomy) can improve recovery. Half of the participants will follow an enhanced recovery protocol, sitting up and walking within hours of surgery and starting liquids early, while the other half r…

This early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…

This phase 2 study tests an oral drug called selpercatinib in 77 people in China who have advanced solid tumors or medullary thyroid cancer with specific RET gene changes. The goal is to see if the drug can shrink tumors and how safe it is. Participants take the pill daily, and d…

This early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks …

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This study tracks how well freezing breast tumors (cryoablation) works together with hormone therapy for women aged 70 and older with low-risk, early-stage breast cancer. Researchers will follow 400 participants for up to 5 years to see how often the cancer comes back. The goal i…

This study tests whether the targeted drug osimertinib can help prevent lung cancer from returning after surgery in patients with uncommon EGFR gene mutations. About 51 adults with stage IB-IIIB non-small cell lung cancer will take an 80 mg pill daily for up to 3 years. Researche…

This study looks at whether people with HER2-positive metastatic breast cancer who have had their cancer controlled for at least three years can safely stop their anti-HER2 therapy. About 82 participants will either stop or continue treatment to see if the cancer stays away for a…

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This phase 3 trial tests whether the immunotherapy drug durvalumab can help people with stage III non-small cell lung cancer that hasn't grown after chemoradiation. About 400 participants receive either durvalumab or a placebo every 4 weeks. The goal is to see if durvalumab delay…

This trial is testing whether an experimental drug called SHR-A1811 can slow the growth of HER2-low breast cancer that has returned or spread, compared to standard chemotherapy chosen by the doctor. The study enrolls about 551 adults whose tumors have low levels of HER2, a protei…

This phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…

This study tests whether adding savolitinib to osimertinib works better than chemotherapy for people with a certain type of advanced lung cancer (EGFR-mutated, MET-positive) that has stopped responding to osimertinib. About 345 adults will be randomly assigned to receive either t…

This study tested whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) works better than standard chemotherapy for people with advanced non-small cell lung cancer. About 950 adults with stage IV lung cancer who had not received prior treatment took part.…

This study tests whether a newer drug, Z-Endoxifen, works better than the standard tamoxifen for postmenopausal women with advanced ER+/HER2- breast cancer. About 81 participants will receive one of the two hormone therapies to see which delays cancer growth longer. The goal is t…

This study tested two immunotherapy drugs (durvalumab and tremelimumab) alone or together against standard chemotherapy for people with advanced non-small cell lung cancer. Over 1,100 adults with no prior treatment took part. The goal was to see if the new treatments helped peopl…

This phase 2 study tests whether combining the immunotherapy drug durvalumab with radiation therapy (without chemotherapy) can delay cancer worsening in people with locally advanced non-small cell lung cancer. About 61 participants will receive radiation plus durvalumab infusions…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This phase III trial compares low-dose tamoxifen to standard hormone therapy (aromatase inhibitors) in postmenopausal women with low-risk, hormone-positive, HER2-negative early breast cancer. The goal is to see if the lower dose works just as well to prevent cancer from coming ba…

This early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants will receive the drug and be m…

This early-stage trial is testing whether combining three drugs—pembrolizumab, guadecitabine, and mocetinostat—can safely treat advanced non-small cell lung cancer (NSCLC) in people whose cancer has progressed after prior immunotherapy. The study aims to find the safest doses of …

This study is for people with advanced non-small cell lung cancer that does not have the PD-L1 marker, making it harder to treat with immunotherapy alone. The trial compares standard immunotherapy (with or without chemotherapy) to the same treatment plus radiation therapy. The go…

This study looks at whether high-dose vitamin D and a home exercise program (walking and strength training) can help prevent bone loss in women being treated for breast cancer. About 191 postmenopausal women with early-stage breast cancer will take either vitamin D or a placebo, …

This study tests different treatments for people with stage III non-small cell lung cancer that cannot be removed by surgery. Participants are grouped by specific genetic markers (biomarkers) to see which therapy works best for their cancer type. The main goal is to see how long …

This study explores whether regular aerobic exercise, specifically walking about 300 minutes per week, can change certain biomarkers in the blood that are linked to cancer risk. Participants are adults who have completed all cancer therapy and have either clonal hematopoiesis (a …

This trial tests whether giving the immunotherapy drug durvalumab before surgery can help women with early, small triple negative breast cancer. Participants receive two infusions of durvalumab, then either proceed to surgery or, if needed, additional standard therapy. The study …

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…

This study tests two new treatments—cabozantinib alone or with nivolumab—against standard chemotherapy for people with advanced non-squamous lung cancer that has returned. The goal is to see if these combinations can slow cancer growth better than current options. About 117 adult…

This phase III trial studies whether adding the immunotherapy drug atezolizumab to standard chemoradiation helps people with limited stage small cell lung cancer live longer. About 544 participants receive either chemoradiation alone or chemoradiation plus atezolizumab. The main …

This phase II trial tests a shorter, higher-dose radiation therapy followed by the immunotherapy drug atezolizumab in 47 patients with stage II or III non-small cell lung cancer who have borderline health. The goal is to see if this approach is safe and effective for people who c…

This early-stage trial tests two drugs, obrixtamig and ezabenlimab, given together as infusions to adults with advanced small cell lung cancer or other neuroendocrine tumors that have a specific marker called DLL3. The main goal is to find the highest safe dose of obrixtamig when…

This study tests whether combining the immunotherapy drug durvalumab with other cancer treatments (with or without chemotherapy) can help control metastatic triple negative breast cancer in people who have not had prior treatment for advanced disease. About 243 women with advance…

This phase III trial is testing two different treatment sequences for people with advanced non-squamous non-small cell lung cancer. One group starts with the immunotherapy drug pembrolizumab alone, then adds chemotherapy only if the cancer progresses. The other group receives pem…

This early-phase trial tests an experimental antibody called GEN1042, given alone or with the cancer drug pembrolizumab (and sometimes chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The main goals are to check …

This trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…

This phase II trial is testing whether combining the targeted drug trametinib with the chemotherapy docetaxel can shrink tumors in people with advanced KRAS-mutant non-small cell lung cancer. The study enrolls 60 patients whose cancer has worsened after one or two prior treatment…

This trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.

This phase 3 trial tests whether adding entinostat to the hormone therapy exemestane helps control advanced hormone receptor-positive breast cancer better than exemestane alone. About 600 patients with locally advanced or metastatic breast cancer are participating. The study meas…

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This study tests whether adding the immunotherapy drug nivolumab after surgery and chemotherapy helps prevent non-small cell lung cancer from coming back. About 900 adults with stage IB to IIIA lung cancer who had their tumor completely removed are participating. The goal is to s…

This early-stage study tests a new drug called GEN1042, which aims to help the immune system fight cancer. It is being tested alone or with other cancer drugs in 42 Japanese adults with advanced solid tumors. The main goal is to check safety and find the right dose.

This early-stage study tests a new drug called BI 1701963, which blocks a cancer-driving protein called KRAS. It is given alone or with an approved drug, trametinib, to adults with advanced solid tumors that have a KRAS mutation and have not responded to prior chemotherapy. The m…

This study tests whether adding the drug veliparib to standard chemotherapy and radiation helps people with stage III lung cancer that can't be removed by surgery. About 53 adults took part to find the best dose and see if the combination slows cancer growth. The goal is to impro…

This study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This early-phase trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy (cisplatin and pemetrexed) before and after surgery can help people with resectable pleural mesothelioma. The study includes 28 participants with stage I-III disease. The…

This large phase 3 trial studied over 5,000 women with hormone receptor-positive, HER2-negative breast cancer that had spread to 1-3 lymph nodes. Participants received standard hormone therapy (tamoxifen or an aromatase inhibitor) either alone or with chemotherapy. The goal was t…

This early-phase trial tests a new drug called BI 764532 (Obrixtamig) given together with standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC), a rare and fast-growing cancer. The study involves about 55 adults whose tumors have a specific marker (DLL3). …

This clinical trial is testing whether a new investigational drug called JS207, which targets two proteins involved in tumor growth (PD-1 and VEGF), can be safely combined with standard chemotherapy as a first-line treatment for advanced non-small cell lung cancer (NSCLC). The st…

This phase 2 trial is testing a drug called tarlatamab in 40 people with advanced small-cell lung cancer or other poorly differentiated neuroendocrine cancers. The drug is given by IV and aims to shrink tumors. Researchers will also study blood and tumor samples to understand why…

This phase 3 study tests whether the targeted drug osimertinib can keep stage III EGFR-mutant lung cancer from progressing after initial chemoradiation. About 216 participants will receive either osimertinib or a placebo daily until their cancer worsens or side effects become una…

This trial tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has returned or not improved after standard treatment. The study has two parts: first, finding a safe dose, and then checking how well the drug works alone or with other chemotherapy.…

This study tests whether adding the drug cediranib to standard chemotherapy (cisplatin and pemetrexed) can help people with malignant pleural mesothelioma, a rare and aggressive lung cancer. In the first phase, researchers found the safest dose of cediranib. In the second phase, …

This Phase 3 trial tests whether a combination of two immunotherapy drugs (acasunlimab and pembrolizumab) works better than the standard chemotherapy docetaxel for people with a specific type of advanced lung cancer (PD-L1 positive NSCLC) that has worsened after prior treatment. …

This early-stage trial tests a new antibody-like drug called BI 764532 alongside standard chemotherapy in adults with advanced small cell lung cancer that has returned after platinum-based treatment. The main goal is to find a safe dose and check for side effects. About 69 partic…

This early-stage study tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …

This study looks at whether using ultrasound before surgery can help identify women with early-stage HR+/HER2- breast cancer who have only a few affected lymph nodes. If so, they may be able to have a less invasive sentinel lymph node biopsy instead of a more extensive axillary l…

This study tests whether adding vericiguat to standard heart failure care can improve heart function in people with breast cancer who developed heart problems after cancer treatment. Participants will be randomly assigned to receive either vericiguat plus usual care or usual care…

This study has two parts. First, it screens people with HR+ HER2-low metastatic breast cancer who are on standard CDK4/6 inhibitor therapy to find those with lingering tumor DNA in their blood—a sign of high relapse risk. Then, those high-risk patients receive the drug trastuzuma…

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This early-phase trial tests whether adding Tumor Treating Fields (TTFields) — a device that delivers electric fields to the tumor — to standard chemoradiation and immunotherapy is safe for people with stage III non-small cell lung cancer that cannot be removed by surgery. About …

This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other anti-cancer medicines in people with metastatic HER2-low breast cancer. The goal is to find safe doses and see if the combination can shrink tumors or slow the cancer's growth. About 138 adults with…

This study tests a radioactive drug called Lutathera added to standard chemotherapy and immunotherapy for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to find a safe dose and see if the combination helps people live longer. About 24 participants…

This study tests whether taking osimertinib for 5 years after surgery can prevent lung cancer from coming back in people with a specific EGFR mutation. About 188 adults with stage II-IIIB non-small cell lung cancer who had their tumor fully removed will take the drug. The main go…

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This Phase 3 trial is testing a new drug called sacituzumab tirumotecan (MK-2870) against standard platinum-based chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer) that has worsened despite prior targeted t…

This phase II trial is testing a procedure called bronchial artery chemoembolization (BACE) combined with systemic anti-cancer drugs in people with advanced non-small cell lung cancer who have no standard treatment options left. BACE delivers chemotherapy directly to the blood ve…

This phase III trial is testing whether adding the drug everolimus to standard hormone therapy can help prevent breast cancer from coming back in women with ER-positive, HER2-negative breast cancer who are at high risk of relapse. Participants have already completed at least one …

This trial investigates whether adding the immunotherapy drug pembrolizumab to standard chemotherapy, both before and after surgery, can improve outcomes for people with resectable non-small cell lung cancer. Participants receive either pembrolizumab plus chemotherapy or a placeb…

This trial is testing whether combining four drugs—anastrozole, palbociclib, trastuzumab, and pertuzumab—can safely and effectively treat HR-positive, HER2-positive metastatic breast cancer as a first-line therapy. The study involves people who have not received prior systemic tr…

This phase 3 trial is testing whether adding an experimental immunotherapy drug called PM8002 to standard chemotherapy (nab-paclitaxel) can help people with advanced triple-negative breast cancer live longer without their disease worsening. The study enrolls women aged 18 to 70 w…

This trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …

This trial investigates whether real-time motion management techniques—like triggered imaging and MLC tracking—can safely reduce the target margins used during radiotherapy for prostate and lung cancer. By adjusting the radiation beam to follow tumor movement, researchers aim to …

This phase 2 trial tests whether adding plinabulin to a standard combination of pembrolizumab and docetaxel can shrink tumors or slow disease progression in people with metastatic non-small cell lung cancer that has worsened after prior immunotherapy. About 47 adults with advance…

This phase 2 trial is testing whether adding an experimental bispecific antibody called JS207—which targets both PD-1 and VEGF—to standard platinum-based chemotherapy can improve outcomes for people with stage II-III non-small cell lung cancer (NSCLC). Participants will receive t…

This phase II trial is testing whether a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and fulvestrant (a hormone blocker)—can slow or stop the growth of a specific type of advanced breast cancer. The study enrolls people with ER-positiv…

This trial tests whether radiation therapy alone can control breast cancer that has spread to nearby lymph nodes as well as surgery to remove those nodes. Women with stage II or III breast cancer who still have cancer in their sentinel lymph node after chemotherapy are randomly a…

This phase 3 trial is comparing an experimental drug, BL-M07D1, against the approved therapy T-DM1 in people with advanced HER2-positive breast cancer that has not responded to previous treatments. The study aims to see whether BL-M07D1 can delay cancer progression better than T-…

This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…

This trial tests whether precisely targeted radiation (SABR) to a small number of growing tumors, while continuing current drug therapy, can delay overall disease progression in people with metastatic non-small cell lung cancer. About 68 participants whose cancer has started to g…

This trial tests a new breast implant called REGENERA in women aged 40–70 who are having a lumpectomy for early-stage breast cancer. The implant is placed during the same surgery to fill the gap left by the removed tumor. The study aims to see if the implant is safe and whether s…

This trial tests an experimental drug called ST316, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors that may have abnormalities in a cell signaling pathway called WNT/β-catenin. The…

This phase 3 trial is testing an experimental oral drug called imlunestrant, alone or combined with abemaciclib, against standard hormone therapies for people with ER+/HER2- advanced or metastatic breast cancer that has worsened after prior hormone treatment. The study aims to se…

This phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…

This study tests a drug called sacituzumab govitecan (Trodelvy) in people with advanced triple-negative breast cancer that has worsened after chemotherapy. The goal is to see how well the drug shrinks tumors and to find biological markers that predict response. Participants recei…

This trial tests whether placing a small marker clip into a breast tumor without ultrasound guidance (using touch alone) is as accurate, safe, and cost-effective as using ultrasound. The study involves 50 women with palpable breast tumors who will receive neoadjuvant chemotherapy…

This study tests different levels of a telephone-based weight loss program for cancer survivors who are overweight or obese. All participants start with a core program including written materials, a smartphone app, and optional coaching. Those who lose at least 2% of their weight…

This phase 2 trial tests whether adding immune-boosting drugs (avelumab and utomilumab) to standard chemotherapy and targeted therapy can help people with HER2-positive metastatic breast cancer whose disease has worsened after prior treatments. Participants are randomly assigned …

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…

This study tests the safety of specially prepared T cells that target a protein called mesothelin, found on some breast cancer cells. The cells are collected from the patient's blood, modified in a lab, and then given back along with chemotherapy and another drug. The trial enrol…

This study tests whether analyzing the genetic makeup of a patient's triple-negative breast cancer tumor can help doctors choose the most effective treatment. Patients with newly diagnosed, early-stage triple-negative breast cancer receive either standard chemotherapy or a person…

This early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…

This phase II trial tests the drug surufatinib, either alone or combined with the chemotherapy vinorelbine, in people with advanced non-small cell lung cancer who have already tried at least two prior treatments. The goal is to see if these treatments can slow tumor growth or shr…

This study looks at whether a 16-20 week exercise and coaching program can reduce inflammation and protect blood vessel health in Black and White women undergoing chemotherapy for breast cancer. Researchers will measure fitness, blood vessel function, and quality of life. The goa…

This trial tests whether combining sacituzumab tirumotecan (a targeted antibody-drug conjugate) with anlotinib (a multi-targeted pill) can shrink tumors or slow cancer growth in people with advanced non-squamous non-small cell lung cancer that has no known driver gene mutations. …

This trial tests whether removing the lung tumor before the lymph nodes, or the lymph nodes before the tumor, leads to better long-term survival in people with early-stage non-small cell lung cancer. About 620 patients will be randomly assigned to one of the two sequences. The st…

This study tests whether using highly focused radiation on each individual brain tumor, instead of radiating the whole brain, can control cancer spread while protecting memory and thinking. It enrolls people with small cell lung cancer who have 1 to 10 brain metastases. Researche…

This trial investigates whether breast cancer patients with cancer in 1-2 sentinel lymph nodes can safely avoid additional armpit surgery (axillary clearance). The study compares survival and cancer recurrence in patients who have the extra surgery versus those who do not. The go…

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This study looks at how well older patients (65 and up) with advanced or metastatic breast cancer tolerate a chemotherapy drug called Abraxane. The goal is to see what side effects occur and whether the drug can control tumor growth. Participants receive Abraxane intravenously, a…

This early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …

This study tests a therapy called CEA CAR-T, which uses a patient's own immune cells modified to recognize and attack cancer cells that carry a protein called CEA. It is for adults aged 18-75 with advanced or recurrent solid tumors (such as lung, colorectal, liver, pancreatic, ga…

This study looks at whether weight-loss surgery (sleeve gastrectomy) combined with lifestyle changes, or lifestyle changes alone, can help women who have had early-stage breast cancer and are obese. The goal is to see if losing weight might lower the chance of the cancer returnin…

This phase 3 trial tests whether a new drug called CT-P51 works as well as the established immunotherapy Keytruda for people with advanced non-squamous non-small cell lung cancer that has not been treated before. All participants also receive standard chemotherapy. The study comp…

This trial investigates whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy and HER2-targeted drugs can destroy more cancer before surgery in people with HER2-positive breast cancer. Participants receive one of three treatment combinations befo…

This phase II trial is testing whether a combination of surufatinib (a targeted therapy), toripalimab (an immunotherapy), and standard chemotherapy can help people with advanced non-squamous non-small cell lung cancer. The study enrolls adults with stage IIIB or IV disease who ha…

This early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…

This pilot study tests whether a resistance training program using weighted sled pushes and pulls can help cancer patients improve muscle mass and reduce body fat. Thirty adults aged 20-89 with a cancer diagnosis will participate in monitored exercise sessions over six months. Re…

This study tests whether giving olaparib (a PARP inhibitor) alone or combined with durvalumab (an immunotherapy) before surgery can eliminate or shrink tumors in people with BRCA-mutated, HER2-negative early breast cancer. Participants receive one of the two treatments for 4–6 mo…

This study tests an experimental pill called JS111 in people with advanced non-small cell lung cancer that has specific EGFR mutations. The goal is to see if the drug is safe and can shrink tumors. Participants take the pill once daily, and the trial will determine the best dose …

This study tests a new drug called WJ47156, alone or combined with other anti-cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of tumor shrink…

This clinical trial is testing whether combining two drugs, palbociclib and bicalutamide, is safe and effective for people with a specific type of metastatic breast cancer that is triple-negative and androgen receptor positive. The study involves women whose cancer has spread and…

This phase 3 trial compares a new drug combination (KN026 plus HB1801, with or without carboplatin) against the standard treatment (trastuzumab, pertuzumab, and docetaxel, with or without carboplatin) in people with early or locally advanced HER2-positive breast cancer. The goal …

This study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…

This early-phase trial tests the safety of combining three drugs—osimertinib, a platinum chemotherapy (cisplatin or carboplatin), and etoposide—in people with metastatic EGFR mutant lung cancer that also has changes in the RB1 and TP53 genes. The goal is to find the highest safe …

This study looks at how well oral vinorelbine, a chemotherapy pill, works in women with advanced breast cancer. It includes women who have already taken the drug or are starting it now. Researchers track how long the cancer stays under control and how patients feel during treatme…

This phase 3 trial compares a new drug, SHR-A1811, to the standard treatment T-DM1 in women with HER2-positive breast cancer who still have cancer cells after initial therapy. The goal is to see if SHR-A1811 can better prevent the cancer from coming back. Participants receive eit…

This phase 2 trial tests whether a vaccine made from a protein found on many triple-negative breast cancer cells can help prevent the cancer from coming back. Participants receive the vaccine along with an immune booster and a low dose of chemotherapy. The study includes women wi…

This early-stage trial tests an experimental drug called SHR-1316, given as a shot under the skin, together with standard chemotherapy (carboplatin and etoposide) in people with extensive-stage small cell lung cancer who have not had prior treatment. The study looks at how the dr…

This pilot trial investigates whether hydroxychloroquine (a malaria drug) and everolimus (an immune-suppressing drug), taken alone or together, can help prevent breast cancer from returning in high-risk patients. The study enrolls people who have completed primary treatment for s…

This trial tests a vaccine called LabVax 3(22)-23, designed to help the immune system recognize and attack a protein called labyrinthin found on adenocarcinoma tumor cells. The study includes adults with advanced or metastatic adenocarcinoma and will evaluate the vaccine alone or…

This phase 3 trial tests whether a new drug combination (MK-7684A) plus chemoradiotherapy helps people with stage III non-small cell lung cancer live longer than the current standard treatment. About 611 participants will receive either the new combo or durvalumab. The study is a…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This phase 3 trial tests whether a daily inhaler containing two bronchodilators (vilanterol and umeclidinium) can help preserve lung function and improve quality of life in people with mild-to-moderate COPD who are undergoing lung cancer surgery. About 204 participants will use t…

This phase 2 trial investigates whether adding the targeted drug palbociclib to standard endocrine therapy (letrozole or tamoxifen) improves tumor shrinkage before surgery in people with hormone receptor positive, HER2 negative breast cancer. The study includes both invasive lobu…

This study tests whether taking enzalutamide for one year after standard treatment is practical for people with early-stage triple negative breast cancer that has androgen receptors. About 50 participants will take the drug and report on their quality of life. The main goal is to…

This phase II trial investigates whether adding two immunotherapy drugs—tiragolumab and atezolizumab—to standard chemotherapy before and after surgery can improve outcomes for people with resectable non-small cell lung cancer. The study enrolls 35 adults with stage II to IIIB dis…

This trial aimed to test a new treatment for advanced lung cancer using specially grown immune cells (LC-CTLs) designed to attack cancer. The study was withdrawn before enrolling any participants, so no results are available. It was planned as an early safety and lab-effectivenes…

This study compares two modern, wire-free methods for locating non-palpable breast lesions before surgery: radioguided occult lesion localization (ROLL) using a radioactive tracer, and magnetic seed localization. The goal is to see which technique more reliably achieves clear sur…

This phase 2 trial tests whether combining the targeted drug adagrasib with immunotherapy (pembrolizumab) and chemotherapy can shrink tumors or delay progression in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The study enrolls adults wh…

This phase 2 trial is testing how well older adults (60+) with advanced HER2+ breast cancer tolerate a combination of two targeted drugs: lapatinib and trastuzumab. The study enrolled 40 participants and focuses on side effects, especially heart-related issues and severe toxiciti…

This phase II trial tests whether adding ivonescimab (an immunotherapy drug) to the current targeted therapy pill can help people with advanced non-small cell lung cancer whose disease is slowly progressing. The study involves 36 adults with a specific EGFR gene mutation. Researc…

This study tests an experimental drug called NEO-201 combined with the immunotherapy pembrolizumab in adults with advanced solid tumors that no longer respond to chemotherapy. The trial focuses on lung, head and neck, cervical, and uterine cancers. Researchers aim to find a safe …

This study tests an experimental drug, imlunestrant, in people with advanced or metastatic breast cancer that is estrogen-receptor positive (ER+), as well as certain other cancers like endometrial cancer. The drug is given alone or combined with other anticancer therapies. The ma…

This phase 2 trial tests whether combining sacituzumab govitecan (a targeted antibody-drug conjugate) with pembrolizumab (an immunotherapy) before and after surgery can improve outcomes for people with resectable non-small cell lung cancer (NSCLC). Participants receive four cycle…

This study tests an experimental drug called CLN-081 in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). Participants must have already received chemotherapy. The goal is to see if the drug is safe and can shrink tumors.

This study is testing whether women over 55 with a specific low-risk type of breast cancer (luminal A) can avoid radiation after lumpectomy. Instead, they take hormone-blocking pills for 5 years. Researchers are tracking 500 women for 10 years to see how many have the cancer come…

This phase 2 trial investigates whether a program of regular walking and a plant-based diet can lower aromatase levels in overweight postmenopausal women with hormone receptor-positive breast cancer who are already taking an aromatase inhibitor. Participants are randomly assigned…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This early study tests whether combining a drug called lurbinectedin with radiation therapy is safe for people with small cell lung cancer that has one new tumor after initial treatment. The drug works by damaging cancer cell DNA, similar to radiation. The goal is to see if this …

This early-stage trial is testing whether focused ultrasound (sound waves aimed at tumors) combined with a low dose of the chemotherapy drug gemcitabine can boost the immune system's ability to fight early breast cancer. About 32 participants will receive either ultrasound, low-d…

This phase 3 trial tests an experimental drug called SY-5007 in people with advanced non-small cell lung cancer that has a specific genetic change (RET fusion). The drug is a daily pill designed to block the cancer-driving RET protein. The study aims to see how well the drug shri…

This study tests whether using MRI brain scans alone to watch for cancer spread is as good as combining MRI with preventive brain radiation in people with small cell lung cancer. The goal is to see if avoiding radiation can reduce side effects and help patients live longer. About…

This phase 2 trial tests whether adding an oral targeted drug called anlotinib to standard chemotherapy can better clear cancer from the breast and lymph nodes before surgery in people with early-stage HER2-negative breast cancer. The study enrolled 31 high-risk patients. The mai…

This phase 3 trial tests whether adding savolitinib to the standard drug osimertinib helps people with a specific type of advanced lung cancer (EGFR-mutant, MET-positive non-small cell lung cancer). About 412 participants will receive either the combination or a placebo plus osim…

This phase 2 trial tests a combination of three types of drugs—an immunotherapy (pembrolizumab), a targeted therapy (lenvatinib), and chemotherapy (pemetrexed plus cisplatin or carboplatin)—as a first treatment for people with advanced malignant pleural mesothelioma that cannot b…

This early study tests a new device that uses electric pulses to destroy malignant lung nodules in people with early-stage lung cancer or limited lung metastases. Five participants will undergo a procedure where a needle is guided into the tumor using CT scans, then delivers elec…

This trial is testing a combination of the immunotherapy drug tislelizumab plus two chemotherapy drugs (albumin-bound paclitaxel and a platinum agent) in 30 people with a specific type of lung cancer called KRAS-mutant non-small cell lung cancer. The participants have advanced or…

This early-phase trial tests whether a DNA vaccine made from a rat HER2 gene can safely stimulate the immune system in people with advanced or high-risk HER2-positive breast cancer. Thirteen participants receive multiple injections of the vaccine at different doses. The main goal…

This study compares two immunotherapy drugs—nivolumab alone versus nivolumab plus ipilimumab—in people with stage IV squamous cell lung cancer that has come back after previous treatment. Participants do not have a specific biomarker that would match them to another targeted ther…

This study tests whether two immunotherapy drugs, balstilimab and botensilimab, are safe and effective as a first treatment for people with metastatic non-small cell lung cancer. The trial includes 45 participants who have not had prior treatment for advanced disease. Researchers…

This study tests whether giving immunotherapy drugs (nivolumab with or without ipilimumab) before surgery is safe and feasible for people with resectable malignant pleural mesothelioma. About 30 adults with epithelial or biphasic mesothelioma will receive the drugs, then undergo …

This phase 3 trial tests whether giving the targeted drug osimertinib (Tagrisso) before surgery, alone or with chemotherapy, works better than standard chemotherapy alone for people with a specific type of lung cancer (EGFR-mutant, non-small cell). About 358 patients with stage I…

This study tests whether using highly focused radiation (SBRT) on a limited number of growing cancer spots can help control the disease in patients with metastatic breast or genito-urinary cancers. Instead of switching to a new drug when some tumors start growing, doctors will ta…

This phase 2 trial is testing the drug taletrectinib in people with a rare, advanced form of breast cancer called invasive lobular carcinoma that has a specific gene change (CDH1 mutation). The study aims to see if the drug can shrink tumors or slow the cancer's growth. The trial…

This study looks at how well a combination of two immunotherapy drugs (nivolumab and ipilimumab), with or without chemotherapy, works as a first treatment for advanced or recurrent non-small cell lung cancer in Japan. Researchers will track about 525 patients to measure survival,…

This early-stage study aimed to test a new mRNA vaccine (CVHNLC) combined with the immunotherapy drug pembrolizumab in people with advanced squamous non-small-cell lung cancer. The trial was designed to find a safe dose and see if the combination could shrink tumors. However, the…

This study tests whether a two-drug combination can help the immune system attack ovarian cancer that has returned after standard treatments. The drugs are E7777, which removes certain immune cells that block the body's defenses, and pembrolizumab, which reactivates cancer-fighti…

This Phase 3 study compares a new drug called YL201 to the standard treatment topotecan in 438 adults with relapsed small cell lung cancer. The goal is to see if YL201 helps people live longer. Participants receive either YL201 by infusion every three weeks or topotecan by inject…

This phase 3 trial tests a new drug called PM8002, which targets the immune system and tumor blood vessels, combined with the chemotherapy paclitaxel. It is for people with small cell lung cancer whose disease has worsened after initial treatment. The study involves 404 participa…

This study tests a new drug called PLB1004 in people with advanced or spreading non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors and how safe it is. About 139 adults who have already tried oth…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in 72 people with a specific type of advanced lung cancer (HER2-mutant non-small cell lung cancer) that has worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors and how safe it …

This trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…

This study looks at whether a special type of mammogram called contrast-enhanced mammography (CEM) can more accurately predict breast cancer in women with suspicious calcium spots in the breast. About 59 women with large areas of these spots will get both a standard mammogram and…

This phase I trial tests an experimental imaging agent called 64Cu-DOTA-pembrolizumab, which is designed to attach to PD1, a protein on immune cells that often cluster around tumors. By injecting this agent and then performing a PET scan, researchers hope to see where these immun…

This early-stage study is testing a radioactive imaging agent called [18F]-C-SNAT4 to see how it travels through the body and whether it can help detect lung cancer on PET scans. About 20 healthy volunteers and people with lung cancer will receive the tracer and undergo scans. Th…

This study tests a special type of mammogram called CESM, which uses a dye injected into a vein to make breast tissue and blood vessels clearer. The goal is to see if CESM is better than standard mammograms at finding the cause of nipple discharge and detecting breast cancer. Abo…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…

This trial is testing an experimental imaging agent called [68Ga]Ga-ELI411, which is designed to bind to a protein (FAP) found in many solid tumors. The study will involve 18 adults with confirmed solid tumors who are already scheduled for a standard FDG-PET scan. Participants wi…

This trial tests whether an AI tool called ENLIGHT can help pathologists more accurately and quickly distinguish between certain lung and kidney cancer subtypes. Pathologists will review digitized slides under three conditions: without AI, with AI as a double-check after their ow…

This study tests a new device that measures blood counts from a tiny finger-prick sample in cancer patients. Researchers will compare these results to standard lab tests from regular blood draws. The goal is to see if the device is accurate enough to eventually allow patients to …

This trial tests whether tomosynthesis (a 3D X-ray technique) combined with synthetic 2D images can reduce the number of advanced and interval breast cancers compared to standard digital mammography. Over 10,000 women scheduled for routine screening will be randomly assigned to o…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study aims to improve early detection of lung cancer in Asian women who have never smoked, a group at higher risk but not covered by standard screening guidelines. Participants receive up to three low-dose CT scans and a blood test designed to spot early signs of cancer. Res…

This early-stage study tests an experimental vaccine designed to prevent cancer in adults with BRCA1 or BRCA2 gene mutations. The vaccine is given alone or with another drug, followed by a mild electric pulse to help it enter cells. Researchers want to see if it is safe and wheth…

This study tests whether a lifestyle program combining aerobic exercise, strength training, and dietary coaching can reduce breast cancer risk in normal-weight postmenopausal women. The goal is to lower body fat and inflammation, which are linked to higher cancer risk even in wom…

This study tests whether a program that includes diet advice, physical activity, stress management, mindfulness, sleep tips, and counseling can help prevent breast cancer in premenopausal women at higher risk. About 60 women will take part to see if the program is practical and w…

This study tests whether sending personalized print materials and a follow-up phone call can encourage women who had childhood cancer to get mammograms. Participants are 360 women aged 25-49 who received chest radiation as children and haven't had a mammogram in two years. The go…

This study tests a natural substance called GM1 to see if it can prevent nerve damage (pain, numbness, tingling) caused by the chemotherapy drug paclitaxel in people with metastatic breast cancer. About 98 participants will receive either GM1 or a placebo alongside their chemo. T…

This study tests whether different amounts of progressive aerobic exercise can reduce risk factors for breast cancer in women who are at high risk. Participants will follow an exercise program, and researchers will measure changes in exercise capacity, body composition, and gene …

This study tests whether a 6-month program combining Bollywood-style dance classes and a fitness tracker can increase physical activity and improve metabolic health in South Asian Indian immigrant women aged 40-65 who are not very active. The goal is to see if this culturally tai…

This study tests whether a mobile application can help breast cancer survivors prevent lymphedema, a common and often permanent swelling of the arm after surgery. Participants who had breast cancer surgery at least one month ago will be randomly assigned to use the app or receive…

This study compares two different doses of radiation aimed at the head (prophylactic cranial irradiation) to see which is better at preventing brain metastases in people with small cell lung cancer. Participants had their lung cancer diagnosed within the past year and have alread…

This study was designed to test whether an oral drug called SPI-1005 could prevent hearing loss and ringing in the ears caused by platinum-based chemotherapy. It was planned for adults with advanced lung or head and neck cancer. The study was withdrawn before enrolling any partic…

This study tests whether a shorter course of higher-dose radiation (hypofractionated) is as good as or better than standard radiation for early-stage breast cancer. About 300 women with ductal carcinoma in situ or early invasive breast cancer are participating. The main goal is t…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This study compares two creams, Aquaphor and Miaderm, to see which one better treats skin irritation caused by radiation therapy in breast cancer patients. About 208 women with early-stage breast cancer will use one of the creams during their radiation treatment. The goal is to f…

This study tests whether a personalized exercise program, guided by video-based movement analysis, can help people with chemotherapy-induced peripheral neuropathy (CIPN) — a common side effect causing numbness, tingling, and balance problems. The trial enrolls adults with breast,…

This study tested a 24-week weight loss program delivered via video calls for 22 breast cancer survivors who were overweight or obese. The goal was to see if the program was practical and well-liked, and whether it improved quality of life, physical activity, and mood. Participan…

This study looks at whether a regular exercise program is practical for women aged 65 and older who are receiving chemotherapy for early-stage breast cancer. Participants will be asked to walk and do arm exercises several times a week. The goal is to see if exercise can reduce th…

This trial asks whether starting sexual health support early and systematically helps women with localized breast cancer feel better about their sexual well-being compared to waiting until they ask for help. Women aged 18 and older who are beginning treatment with surgery will re…

This study tests a 12-week mobile health program for 304 young adult cancer survivors (ages 18-39) who finished treatment within the last 5 years. The program combines social support and mindfulness training to encourage moderate-to-vigorous physical activity. The goal is to see …

This study tests whether an AI system that analyzes social media posts can improve quality of life for breast cancer patients. 440 women will either use the AI system plus usual care or just usual care for 6 months. The goal is to see if personalized emotional support reduces anx…

This phase 2 study tests whether acupuncture can improve memory, focus, and thinking problems (often called 'chemo brain') in people who have had breast, colorectal, prostate, or gynecological cancer. About 48 participants will receive either real acupuncture or sham (fake) acupu…

This study looks at whether a mobile health program that combines physical activity tracking with mindfulness lessons can help breast cancer survivors become more active and feel better. About 304 women who finished cancer treatment within the past 5 years will take part in a 24-…

This study tests whether an internet-based pain coping skills program can help cancer survivors manage ongoing pain. About 456 adults who have completed cancer treatment or are on maintenance therapy will take part. Participants will either get the online program plus enhanced us…

This study tests if fast-acting opioids (fentanyl or morphine) can reduce shortness of breath during or after walking in 150 cancer patients who already take strong painkillers. Participants will take the drug or a placebo before a short walk test, and researchers will measure ch…

This study tests whether an open labeled placebo—a pill with no active medicine that patients know is a placebo—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply takin…

This study looks at whether women aged 65 and older with early-stage, estrogen-positive breast cancer can safely have a lumpectomy without also removing and testing nearby lymph nodes (sentinel node biopsy). The goal is to see if skipping this extra step leads to cancer coming ba…

This trial tests whether a virtual reality (VR) educational video can reduce anxiety and improve satisfaction in adults starting their first course of external beam radiotherapy for cancer. Half of the 122 participants will watch a VR video through a headset before treatment, whi…

This study tests an online pathway called iPath*D that guides cancer patients who report depression symptoms from screening to treatment options. The goal is to see if the tool is acceptable and easy to use for adults starting cancer treatment. Researchers will measure usability,…

This study tests the DISCO app, designed to help cancer patients talk with their doctors about treatment costs. About 254 adults newly diagnosed with breast, prostate, lung, or colorectal cancer will use the app to become more confident in asking cost-related questions. The goal …

This study tests a digital program called EMBody for cancer survivors aged 16-25 who finished treatment up to seven years ago. The program uses short films and reflection activities to help them develop a healthier mindset about their body. Researchers want to see if it improves …

This trial tests whether acupuncture can prevent taxane-induced peripheral neuropathy (TIPN) — nerve damage causing pain and tingling in arms and legs — from worsening in breast cancer patients receiving weekly taxane chemotherapy. Participants with early-stage breast cancer who …

This study tests whether group education sessions can help veterans with newly diagnosed cancer discuss their goals of care and complete advance directives. Fifty veterans will attend two virtual or in-person sessions led by a trained health educator. Researchers will check if th…

This trial tests whether adding bupivacaine, a numbing medicine, directly into the surgical wound after a mastectomy can improve pain control and reduce the need for opioid painkillers. Participants receive either bupivacaine or a placebo through a drain placed in the wound, alon…

This study looks at whether a simple exercise program is practical and helpful for people with non-small cell lung cancer who are getting radiation therapy, along with their family caregivers. About 40 pairs (patient and caregiver) will take part. The goal is to see if exercising…

This study tests whether a supervised, home-based exercise program can help people with metastatic cancer who are starting oral targeted therapy. Participants are randomly assigned to either a weekly 60-minute session with a trained coach or to a booklet with exercise recommendat…

This study tests whether rituximab or tocilizumab can help people with advanced cancer stop taking steroids for side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can safely reduce or stop steroid treatment within 4 weeks. Th…

This trial tests whether a three-week physiotherapy program, starting one week after breast reduction surgery, can reduce pain, improve posture, and boost quality of life. Forty women aged 18 to 50 who have had their first breast reduction will be split into two groups: one recei…

This trial tests a mindfulness program that blends stress-reduction techniques with Christian principles to improve well-being in Black adult cancer survivors. Participants take part in a silent mindfulness retreat, focus groups, interviews, and questionnaires. The study measures…

This trial explores whether inhaling essential oils like peppermint, lavender, or ginger can help reduce nausea and anxiety in cancer patients receiving chemotherapy infusions. Current anti-nausea drugs often cause constipation and fatigue, so researchers are looking for gentler …

This study tests whether a 12-week home exercise program, guided by telehealth check-ins, can reduce fatigue in cancer survivors living in rural Colorado. Participants follow a personalized plan of aerobic and resistance exercises, with intensity adjusted based on their progress.…

This trial looks at whether supervised aerobic exercise is more beneficial when done during chemotherapy or after it ends for women with early-stage breast cancer. Participants are randomly assigned to exercise during treatment, after treatment, or to receive only educational mat…

This study tests whether Moutan Cortex, a Chinese herb containing paeonol, can relieve nerve pain and numbness caused by chemotherapy in breast cancer patients. Participants take the herb or a placebo daily for four weeks. Researchers measure pain levels and nerve function to see…

This study tests whether an online pain coping skills training program can reduce joint, bone, and muscle pain in breast cancer survivors who take aromatase inhibitors (AIs). Participants are women who have completed primary cancer treatment and experience AI-related joint pain. …

This study tests whether sexual counseling delivered via WhatsApp can help breast cancer survivors who have sexual problems after treatment. About 86 women who have had mastectomy and finished chemo/radiotherapy will receive counseling using the EX-PLISSIT model. The goal is to s…

This pilot study tests the drug ruxolitinib in people with advanced non-small cell lung cancer who are experiencing cancer cachexia—unintended weight loss and muscle wasting. The main goal is to check for side effects and see how the drug affects body signals related to appetite …

This study tests whether structured hypnotherapy sessions can improve quality of life for women with breast cancer undergoing chemotherapy. Participants in the intervention group receive 10 hypnotherapy sessions alongside standard care, while the control group receives standard c…

This study explores whether a structured survivorship care visit, conducted early in cancer treatment, can help reduce psychological distress and improve quality of life. Adults with any type of cancer who report significant distress will meet with a physician assistant to discus…

This study tests whether an over-the-counter herbal pain patch, called Tibetree Pain Relieving Plaster, can reduce muscle and joint pain in people who have finished active cancer treatment. Sixty-eight cancer survivors will apply either the active patch or a placebo patch to thei…

This study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…

This study compares two types of nerve blocks (retrolaminar block vs. serratus anterior plane block) to see which provides better pain relief after radical mastectomy. About 90 women aged 25-65 undergoing breast cancer surgery will receive one of the blocks before general anesthe…

This study tests whether a phone app can help people with chest-area cancers and their caregivers report symptoms early and request palliative care on their own. The goal is to improve quality of life by managing pain and stress sooner. About 157 participants will use the app to …

This pilot study tests a support program called CASA for people with advanced cancer and their caregivers. The program includes five counseling sessions to help with spiritual well-being and emotional distress. Researchers will enroll 124 participants to see if the program is hel…

This study tests whether a 6-week online yoga program can improve quality of life, reduce joint pain, and lessen night sweats and hot flashes in women with breast cancer who are taking endocrine therapy. About 64 women will take part, with half doing yoga four days a week and the…

This study tested if a scalp cooling cap set to a colder temperature than usual can safely prevent hair loss in breast cancer patients receiving chemotherapy. 34 adults with stage I-III breast cancer took part. The goal was to see if the lower temperature is safe and tolerable.

This study tests whether a cream made with caffeine can help prevent skin hardening and other complications in breast cancer patients who need radiation after mastectomy with tissue expander reconstruction. About 60 participants will use either the caffeine cream or a placebo cre…

This study compares listening to Holy Qur'an recitation versus calming music before bed in children aged 6 to 10 who are undergoing chemotherapy. Sleep problems are common in these children, and the goal is to find a safe, non-medication way to improve sleep quality. Ninety child…

This study collects blood, urine, and tumor tissue from 500 adults with breast, ovarian, or uterine cancer, plus some of their relatives. The goal is to create a repository of samples for future research on DNA changes that drive these cancers. Participants give samples during ro…

This study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …

This study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…

This study is testing whether a blood test that looks for tumor DNA can help doctors decide when to safely stop immunotherapy in people with advanced melanoma or non-small cell lung cancer. About 39 patients who have been on immunotherapy for at least a year and show no signs of …

This study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.

This Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safe…

This study is testing whether regular screening for prostate, lung, colorectal, and ovarian cancers can reduce deaths from these diseases. About 154,900 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers are tracking cancer c…

This study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…

This study follows women with early-stage breast cancer who are about to receive paclitaxel chemotherapy, a treatment that often causes nerve damage. Researchers will use smartwatches and a mobile app to track physical activity, sleep, and stress, alongside clinical exams and ski…

This study aims to understand the experiences of cancer patients who receive care at home through MD Anderson's Care and Monitoring at Home program. Researchers will use surveys to measure quality of life and gather feedback from up to 40 participants. The goal is to learn whethe…

This trial tests whether a structured, nurse-led symptom screening program can increase the number of cancer survivors who are screened for distress and referred to supportive services. The program includes nurse training and regular feedback, and it will be rolled out across mul…

This pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…

This study tested whether radiologists can safely skip looking at detailed 3D breast scans when a quick 2D image or an AI score suggests the case is normal. Sixteen radiologists briefly viewed each case and rated how likely it was normal, then saw the AI's opinion. The goal is to…

This study collects white blood cells and tumor cells from cancer patients, and white blood cells from healthy volunteers, to help researchers grow anti-cancer cells in the lab. The goal is to create experimental cell therapies for future use. Up to 7,000 participants will provid…

This study investigates whether early changes on a PET scan can predict which patients with HER2-positive breast cancer will have a complete response to a combination of trastuzumab and pertuzumab given before surgery. Participants receive the two drugs and undergo PET scans at t…

This study tests whether a simple questionnaire, filled out by children and teens with cancer (and their caregivers) before and after a clinic visit, can help doctors better understand their symptoms. About 85 participants will use the tool during routine visits. The goal is to s…

This study aims to find out how often cancer patients treated with opioids for pain are at risk of misusing these medications. Researchers will use two screening questionnaires to assess misuse risk in 200 adult outpatients receiving opioids for cancer-related pain. The findings …

This study looks at how safe and doable different amounts of aerobic exercise are for people about to have surgery for solid tumors like breast, endometrial, or prostate cancer. About 60 participants will exercise at home while using apps and devices to track their activity. The …

This study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …

This study follows breast cancer patients who have had curative surgery and are receiving hypofractionated radiation therapy—shorter treatment courses lasting one to three weeks. Researchers will track changes in breast skin, fibrosis, cosmetic appearance, and patient-reported ou…

This study looks back at medical records of 50 Chinese adults with advanced ALK-positive non-small cell lung cancer who received lorlatinib as their first treatment. Researchers want to learn about patient characteristics, such as age and smoking history, and how the drug is used…

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study is investigating whether genetic changes in tumor tissue and blood can predict how well people with hormone receptor-positive metastatic breast cancer respond to a combination of endocrine therapy and palbociclib. Researchers will collect tumor samples and blood from p…

This study looks at whether certain genes make African American women with breast cancer more likely to develop nerve damage (pain, numbness, tingling) from common chemotherapy drugs called taxanes. About 249 women with stage I-III breast cancer will receive either docetaxel or w…

This study looks at whether a dye called iohexol can help doctors better calculate the dose of the chemotherapy drug carboplatin for cancer patients. The goal is to make sure patients get the right amount of drug to fight their cancer while reducing side effects. About 318 men wi…

This study is looking at why some people develop persistent pain after breast cancer surgery while others do not. Researchers will follow 220 adults undergoing breast cancer surgery, using questionnaires and a pain sensitivity test to identify risk factors. The goal is to find re…

This study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…

This study tests whether giving smokers and former smokers a personalized risk report (based on clinical and genetic factors) helps doctors order lung cancer screening and helps patients follow through. About 915 participants will be randomly assigned to usual care or one of two …

This study collects tissue and blood samples from 1,200 adults with known or suspected cancer. The samples are taken during standard surgeries or biopsies, with no extra procedures. Researchers will compare cancerous and normal tissues to identify differences that could lead to n…

This study looks at whether a mobile health program combined with social media can help teens and young adults who survived childhood cancer become more physically active. About 387 participants will either use the program plus a fitness tracker or just the tracker alone. The goa…

This study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…

This study looks at what happens when older smokers (ages 50-80) who are at high risk for lung cancer switch from regular cigarettes to e-cigarettes. Researchers will track how many cigarettes they smoke and measure health markers like inflammation in their blood. The goal is to …

This large study (ALCHEMIST) is screening over 8,000 people with early-stage non-small cell lung cancer to analyze the genes in their tumors. The goal is to identify genetic changes that could help doctors choose the best treatments, such as targeted therapies. Participants provi…

This study aims to create a large collection of blood and tissue samples from people with breast cancer, as well as those at high risk. The samples will be stored and used for future research to better understand, diagnose, and treat breast cancer. Participants will also be asked…

This study aims to learn more about how inherited gene mutations, particularly in the BRCA1 and BRCA2 genes, affect the risk of developing breast and ovarian cancer. Researchers will follow participants with a family history of these cancers, tracking their medical history and fa…

This study is for women with breast cancer who are receiving a treatment that greatly lowers estrogen levels. Researchers want to see if this treatment changes how the heart works. They will use heart scans to measure blood flow in 90 women over two years. The goal is to learn mo…

This study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…

This study taps into Sweden's national health registers to examine outcomes for thousands of adults who have undergone thoracic surgery, including procedures for lung cancer and pulmonary metastases. By linking detailed patient data, researchers aim to identify factors associated…

This study looks at how cancer patients use complementary and alternative medicine (CAM), such as herbal products and aromatherapy. Researchers will survey 500 patients and hold focus groups with 30-60 survivors to understand their needs, information sources, and any potential sa…

This study is looking at how often people with small cell lung cancer also have symptoms of Lambert-Eaton myasthenic syndrome (LEMS), a condition that affects the nerves and can cause muscle weakness. Researchers will review medical records and check for LEMS symptoms in adults d…

This study explores whether a remote, direct-to-patient approach can improve how people with small cell lung cancer (SCLC) are reached and engaged in clinical research. It involves collecting biospecimens and surveying patients about their preferences and needs regarding new ther…

This study is for adults with advanced head and neck, lung, or skin cancer who have not responded to prior treatments. Researchers use special PET scans to see how two experimental drugs (BI 765063 and BI 770371) travel through the body and reach tumors. Participants receive one …

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study looks back at medical records of 150 women with breast cancer to compare two minimally invasive ways of checking whether cancer has spread to lymph nodes under the arm: robotic-assisted and endoscopic-assisted sentinel lymph node biopsy. The goal is to see which method…

This study is looking at how triple-negative breast cancer evolves during chemotherapy. Researchers will take biopsies from the tumor before, during, and after treatment to see if the diversity of cancer cells affects how well the tumor responds. The goal is to understand why som…

This study looks at whether two different health programs are practical and acceptable for women who have finished treatment for early-stage breast cancer. One program combines nutrition advice, lifestyle changes, yoga, and therapeutic touch (Ayurveda). The other is a self-guided…

This study is testing whether a new device called Liberty can accurately measure blood counts from a finger-prick sample compared to standard venous blood draws. Researchers will collect paired capillary and venous blood samples from healthy volunteers and cancer patients receivi…

This trial investigates whether comprehensive genomic analysis of tumor tissue can help doctors choose targeted therapies for patients with advanced non-small cell lung cancer. Participants provide tumor samples (from past biopsies or new ones) for genetic testing. The goal is to…

This large observational study looks at whether getting an mRNA COVID-19 vaccine shortly before or after starting immune checkpoint inhibitor therapy is linked to longer survival in adults with cancer. Using data from nearly 100,000 patients in France, researchers are comparing t…

This study uses a special PET scan to measure brain inflammation in women with stage II–III breast cancer before and after chemotherapy. The goal is to see whether higher levels of inflammation are linked to memory and thinking problems, often called 'chemo brain.' Twenty women w…

This study looks at medical records from Europe and Canada to understand how immunotherapy is used in people with non-small cell lung cancer who have had surgery. It tracks patient characteristics, treatments before and after surgery, and outcomes like survival and complications.…

This study combines MRI scans with detailed genetic and molecular analysis (multiomics) to improve how luminal breast cancer is classified and treated. Researchers aim to develop models that predict treatment resistance, recurrence, and spread, helping doctors choose the most eff…

This study looks at whether taking muco-active agents (mucus-thinning drugs like N-acetylcysteine and ambroxol) after a lung cancer diagnosis is linked to better outcomes in people who also have COPD. Researchers will analyze data from a large Korean database, comparing those who…

This study looks at how the drug ribociclib is actually used in everyday medical practice for people with a common type of early breast cancer (HR+/HER2-). Researchers will analyze medical records from thousands of patients to see who gets the drug, how long they take it, and wha…

This study investigates whether bioimpedance analysis, a quick and painless test that measures body water and muscle mass using a weak electrical current, can help predict complications after lung cancer surgery. Researchers will compare these measurements with standard CT scans …

This study examines whether changes in the LKB1 gene can help predict how well people with non-small cell lung cancer respond to treatments like chemotherapy, targeted therapy, and immunotherapy. Researchers will analyze tumor samples and medical records from about 300 patients t…

This study explores whether genetic testing from a simple saliva sample can improve risk assessment for breast cancer in women who need a breast biopsy. Researchers will analyze DNA from saliva to calculate a polygenic risk score and compare it with biopsy results and medical rec…

This study is developing an artificial intelligence model that can analyze frozen-section pathology images—tissue samples examined during surgery. The goal is to help pathologists quickly and accurately diagnose cancer while the patient is still in the operating room. Researchers…

This study explores whether a Nectin-4 PET scan can predict how well a Nectin-4-targeted therapy works in people with advanced breast cancer. Forty participants will receive both a standard PET scan and a Nectin-4 PET scan before starting treatment, and some will have a repeat sc…

This study tests whether teaching breast self-examination using pictures, models, and hands-on demonstrations can increase breast cancer awareness and health motivation in illiterate women aged 15-49 living in rural Turkey. Participants receive face-to-face visual education and a…

This study looks back at medical records of 300 people with metastatic luminal A or luminal B breast cancer who were treated with CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib). The goal is to see how long patients lived without their cancer getting worse, and whethe…

This study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …

This study collects extra tissue and a small blood sample from people undergoing standard procedures for lung cancer. Researchers will use these samples to grow miniature versions of the tumors, called organoids, in the lab. The goal is to study how lung cancers grow and change, …

This study looks at how chronic noncommunicable diseases like inflammatory bowel disease and breast cancer impact a person's ability to work. Researchers will follow 200 working-age adults for 12 months, collecting data on health, work performance, and well-being. The goal is to …

This study follows 900 cancer survivors from six small island nations (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia, and Saint Vincent) to understand how traveling overseas for cancer treatment affects their health and social support. Researchers will compare those who se…

This study compares two minimally invasive techniques for removing lymph nodes under the arm in people with breast cancer that has spread to those nodes. The goal is to see which method better protects nearby nerves, reduces side effects like numbness or pain, and improves recove…

This study follows people who have received photodynamic therapy (PDT) for various cancers, including head and neck, lung, and skin tumors. PDT uses a light-sensitive drug and a special light to destroy cancer cells while sparing healthy tissue. Researchers will review medical re…

This trial tests whether a pharmacist-led educational program helps cancer patients on high-risk chemotherapy better understand and follow neutropenic precautions—steps to prevent serious infections when white blood cell counts are low. About 300 adults with various cancers will …

This study creates a registry of cancer patients who have had their tumor genes analyzed. Participants fill out a 10-minute survey about their exercise habits before and after diagnosis. Researchers will look for connections between physical activity and genetic changes in tumors…

This study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…

This study tests whether giving cancer patients a drug vigilance card helps them avoid medication errors and interactions when seeing other doctors. One hundred patients on oral chemotherapy or targeted therapies at Limoges University Hospital will use the card. Researchers will …

This long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…

This study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…

This study aims to create a comprehensive precision oncology platform at the Chinese University of Hong Kong to personalize drug therapy for 170 patients with advanced gastrointestinal cancers. Researchers will collect tumor samples for genetic sequencing and grow patient-derived…

This study follows 305 people with stage III non-small cell lung cancer who have specific genetic mutations. Researchers regularly test their blood for tiny traces of cancer DNA (minimal residual disease, or MRD) to see if it can predict when the cancer will come back. The goal i…

This study examines whether a routine blood test called Mean Platelet Volume (MPV), taken when a cancer patient is admitted to the intensive care unit (ICU), can help predict their risk of dying. Researchers will review the medical records of 425 adult cancer patients who stayed …

This study checks the eye health of people with breast cancer using standard tests like vision charts, eye exams, and scans. The goal is to spot any vision changes or eye damage that might happen during cancer treatment. About 160 participants will be followed to understand how b…

This study tests five different reminder strategies to encourage women in Singapore who are overdue for mammograms to get screened. About 12,750 women aged 50-69 who have not had a mammogram in over two years will receive reminders by mail, with some getting a pre-scheduled appoi…

This study asks 12 clinicians in Florida who care for women with breast cancer about gaps in emotional and mental health support. They will join virtual focus groups and fill out a short survey. The goal is to use their insights to build an AI-powered digital platform called Mamm…

This study aims to understand why some people who have never smoked develop lung cancer. Researchers are comparing the genes of never-smokers with lung cancer to those without the disease. The goal is to find genetic differences that might increase risk. This is a research study …

This study looks at how to best collect information about social and behavioral needs (like housing, food, or transportation) from women newly diagnosed with breast cancer. Researchers will compare different screening tools and methods (like chatbots or phone calls) to see which …

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study looks at whether regular blood tests can detect changes in stage IV breast cancer during treatment. Researchers will collect blood samples from 150 adults with metastatic breast cancer and analyze them for tumor DNA. The goal is to see if these tests can spot when the …

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study at Johns Hopkins is testing whether genetic information from a blood sample can match what is found in a tumor biopsy for people with metastatic breast cancer. Researchers will use the results to suggest personalized treatment options. The goal is to see if a simple bl…

This study looks at genetic changes in blood and tumor samples from women with advanced hormone receptor-positive, HER2-negative breast cancer who are being treated with palbociclib and endocrine therapy. By comparing genetic material from the cancer tissue with that found in the…

This study analyzed stored tumor samples and medical records from nearly 1,900 Greek women who had surgery for early breast cancer. Researchers looked at genetic changes and protein markers in the tumors to see how they relate to breast cancer subtypes and long-term survival. The…

This study looks at how age changes the way the body handles a breast cancer drug called nab-paclitaxel. Researchers are studying 40 people with metastatic breast cancer to see if older patients process the drug differently. The goal is to make chemotherapy safer and more effecti…

This study looks at attention and memory in breast cancer survivors compared to healthy women of the same age. Researchers use EEG to measure brain activity during memory tasks. The goal is to understand why some survivors have trouble focusing or remembering. Results may help de…

This study looks at how the activity of an enzyme called DPD influences how well the chemotherapy drug capecitabine works in women with metastatic breast cancer. Researchers will measure DPD activity before treatment and track tumor response over 24 months. The goal is to see if …

This study tests whether an AI system can create safe and effective exercise plans for women recovering from breast cancer surgery. Researchers will compare the AI's plans to those made by doctors. The goal is to make rehabilitation more personalized and accessible.

This study looks at why some women with breast cancer in one breast later develop cancer in the other breast. Researchers are comparing women with cancer in both breasts to those with cancer in only one breast. They are studying how genes, past radiation treatment, and lifestyle …

This study examines whether medications given during mastectomy to keep blood pressure stable might affect the risk of breast cancer coming back. Researchers will review the records of 250 patients who had mastectomy over five years. They will look at which drugs were used and tr…

This study tested a program to help cancer patients understand their fertility risks and get the right care. It included 434 women aged 15-55 with a new cancer diagnosis. The program aimed to connect them with specialists for pregnancy planning or fertility preservation based on …

This study looks at how breast cancer treatment impacts women's jobs, finances, and daily life, especially comparing women from different ethnic groups. About 935 breast cancer survivors who were working before or during treatment will share their experiences. The goal is to unde…

This study collects blood, urine, and tissue samples from 330 adults with advanced lung or head and neck cancer to improve precision medicine. Researchers will analyze genetic changes in these samples and grow some tumors in mice to compare DNA. The goal is to refine liquid biops…

This early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…

This study creates a long-term repository of blood, tissue, and health information from 810 people with breast cancer, benign breast disease, or no breast issues. The goal is to provide researchers with resources to better understand breast cancer. No treatment or experimental th…